Should investors be concerned about NVCR's Q4 2024 EPS?

**Investors should not be overly concerned about NVCR's Q4 2024 EPS.** Here's why:

1. **Analyst Forecasts**: Wedbush, a reputable financial firm, has raised its FY2024 EPS estimate for NovoCure, forecasting a Q4 2024 EPS of ($1.26), which is higher than the previous estimate of ($1.40). This indicates a potential improvement in earnings.
2. **Recent Performance**: NovoCure's recent quarterly earnings report showed a reported EPS of ($0.28) for the quarter ended September 30, 2024. This was higher than the same quarter last year's EPS of -($0.46) and beat the consensus estimate of -($0.33).
3. **Revenue Growth**: The company's revenue for the quarter was up 21.8% compared to the same quarter last year, reaching $155.10 million, surpassing analyst estimates of $143.95 million.
4. **Institutional Confidence**: Institutional investors have shown confidence in NovoCure, with several hedge funds and pension funds increasing their holdings in the company. This suggests that these investors do not perceive Q4 2024 EPS as a significant concern.
5. **Price Target and Rating**: The stock has received positive attention from analysts, with HC Wainwright upgrading NovoCure to a "buy" rating, and Wedbush maintaining an "outperform" rating, indicating a positive outlook for the stock.

While it's important for investors to monitor earnings reports and EPS, the overall trajectory of NovoCure's earnings is showing improvement, and the forecasts for Q4 2024 suggest a positive outlook. However, investors should continue to track the company's performance and any market conditions that may impact its financial results.